科技之光,研發(fā)未來(lái)-特殊染色技術(shù)服務(wù)檢測(cè)中心
常規(guī)HE染色技術(shù)服務(wù)檢測(cè)中心:專業(yè)、高效-生物醫(yī)學(xué)
科研的基石與質(zhì)量的保障-動(dòng)物模型復(fù)制實(shí)驗(yàn)服務(wù)檢測(cè)中心
科技之光照亮生命奧秘-細(xì)胞熒光顯微鏡檢測(cè)服務(wù)檢測(cè)中心
揭秘微觀世界的窗口-細(xì)胞電鏡檢測(cè)服務(wù)檢測(cè)中心
科研的基石與創(chuàng)新的搖籃-細(xì)胞分子生物學(xué)實(shí)驗(yàn)服務(wù)檢測(cè)中心
科研的堅(jiān)實(shí)后盾-大小動(dòng)物學(xué)實(shí)驗(yàn)技術(shù)服務(wù)檢測(cè)中心
推動(dòng)生命科學(xué)進(jìn)步的基石-細(xì)胞生物學(xué)實(shí)驗(yàn)技術(shù)服務(wù)
科技前沿的守護(hù)者-細(xì)胞藥效學(xué)實(shí)驗(yàn)服務(wù)檢測(cè)中心
科研前沿的探索者-細(xì)胞遷移與侵襲實(shí)驗(yàn)服務(wù)檢測(cè)中心
IdeS Protease全稱免疫球蛋白G降解酶,酶活(Enzymeactivity)40U/μL酶活定義(UnitDefinition)在37℃條件下,反應(yīng)30min,剪切>95%的1μg重組單克隆IgG所需要的酶量定義為一個(gè)活性單位。儲(chǔ)存條件-25~-15℃保存,有效期1年。使用方法1.在消化液中加入適量IgG(加至5mg);2.在IgG樣本中加入IdeS蛋白酶(每1μgIgG加入1個(gè)單位的IdeS);3.將樣品置于37℃孵育30-60min。IdeS蛋白酶在中性pH或接近中性pH的緩沖中活性強(qiáng)。推薦反應(yīng)緩沖是50mM磷酸鈉,150mMNaCl(pH6.6),多數(shù)常見的生物緩沖也適用,比如Tris或PBS;注意:不在此pH范圍(例如乙酸鹽緩沖液)的緩沖也可能適用,但是孵育時(shí)間或酶量需要根據(jù)實(shí)際情況進(jìn)行優(yōu)化。注意事項(xiàng)1.IdeS不能識(shí)別切割小鼠IgG1/IgG2b,大鼠、豬、牛和山羊IgG,對(duì)小鼠IgG2a和IgG3具有中等酶切活性,酶切小鼠IgG2a和IgG3建議增加IdeS的用量(推薦用量為正常用量的5-10倍)。2.IdeS不能切割非IgG亞型的單抗分子,包括IgA、IgM、IgD和IgE。IdeS Protease全稱免疫球蛋白G降解酶是由人類致病菌釀膿鏈球菌產(chǎn)生并分泌至胞外的一種半胱氨酸水解酶。Recombinant Human APOE4/Apolipoprotein E Protein,HisTag
Angiotensin I Converting Enzyme (ACE-2), also called ACEH (ACE homologue), is a dimeric, zinc-dependent metalloprotease of the ACE family that also includes somatic and germinal ACE. ACE-2 mRNA is found at high levels in heart, testis, and kidney and at lower levels in a wide variety of tissues. ACE-2 is the SARS-CoV and SARS-CoV2 Spike protein receptor in vivo, functions catalytically as a carboxypeptidase to cleave several substrates including angiotensins I and II, and acts as a partner for B0AT1-family amino acid transporters. Through these functions, ACE-2 has been shown to be involved in several diseases including SARS, COVID19, acute lung injury, heart disease, liver and lung fibrosis, inflammatory lung disease, and cardiopulmonary disease . Full length ACE-2 protein includes an extracellular region composed of a single N-terminal peptidase domain and C-terminal collectrin-like domain (CLD), a transmembrane domain, and a short cytoplasmic tail. The N-terminal peptidase region is required for binding to SARS-CoV and SARS-CoV2 spike proteins, while the CLD contains a region that promotes dimerization and association with amino acid transporters.Recombinant Protein L (Freeze-Dried) 重組蛋白L(凍干)LAG-1與MIP-1β(ACT II同種型)相同,Lag-1趨化吸引力單核細(xì)胞,并表現(xiàn)出活性作為HIV抑制因子。
Recombinant Biotinylated Human MSLN/Mesothelin Protein,hFc-Avi Tag分子別名(Synonyms)Mesothelin;CAK1;MSLN;MPFSMRP表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)BiotinylatedHumanMSLN/MesothelinProteinisexpressedfromHEK293withhFctagandAvitagattheC-Terminus.ItcontainsGlu296-Gly580.[Accession|Q13421-2]分子量大小(MolecularWeight)TheproteinhasapredictedMWof61.1kDa.Duetoglycosylation,theproteinmigratesto70-80kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.活性(Activity)ELISAData:ImmobilizedAnti-MSLNAntibody,hFcTagat1μg/ml(100μl/well)ontheplate.DoseresponsecurveforBiotinylatedHumanMSLN,hFcTagwiththeEC50of18.4ng/mldeterminedbyELISA.
Recombinant Biotinylated Human AFP (HLA-A*02:03) Protein,His-Avi Tag性能參數(shù)表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)RecombinantBiotinylatedHumanAFP(HLA-A*02:03)ProteinisexpressedfromHEK293withHistagandAvitagattheC-terminal..ItcontainsGly25-Thr305(HLA-A*02:03),Ile21-Met119(B2M)andFMNKFIYEIpeptide.[Accession|AAA03604.1(HLA-A*02:03)&P61769(B2M)&FMNKFIYEI]分子量大?。∕olecularWeight)TheproteinhasapredictedMWof50.70kDa.Duetoglycosylation,theproteinmigratesto53-60kDabasedonTris-BisPAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedby>95%asdeterminedbyHPLC制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugetubesbeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.D還具有抑制髓樣細(xì)胞增殖的能力,髓樣細(xì)胞增殖是Eotaxin不共有的生物學(xué)功能。
Dabigatranetexilatemesylate,又稱甲磺酸達(dá)比加群酯,是可口服的凝血酶抑制劑,是一種抗凝藥,通過(guò)競(jìng)爭(zhēng)結(jié)合凝血酶的纖維蛋白特異結(jié)合位點(diǎn),阻礙纖維蛋白生成,從而抑制血栓的形成。產(chǎn)品信息英文別名(EnglishSynonym)Dabigatranetexilatemesylate,Pradaxa,BIBR1048MS,Dabigatranetexilatemethanesulfonate中文名稱(ChineseName)甲磺酸達(dá)比加群酯,達(dá)比加群酯甲磺酸鹽靶點(diǎn)(Target)Thrombin通路(Pathway)Protease/MetabolicEnzyme--ThrombinCAS號(hào)(CASNO.)872728-81-9分子式(Formula)C35H45N7O8S分子量(MolecularWeight)723.84外觀(Appearance)粉末純度(Purity)≥98%溶解性(Solubility)溶于DMSO運(yùn)輸和保存方法-25~-15℃保存,有效期3年。使用方法【數(shù)據(jù)來(lái)自于公開發(fā)表的文獻(xiàn),供參考,具體使用濃度請(qǐng)參考相關(guān)文獻(xiàn),并根據(jù)自身實(shí)驗(yàn)條件(如實(shí)驗(yàn)?zāi)康模?xì)胞種類,培養(yǎng)特性等)進(jìn)行摸索和優(yōu)化。】動(dòng)物實(shí)驗(yàn)(體內(nèi)實(shí)驗(yàn))在體內(nèi),口服dabigatranetexilate在大10-50mg/kg)和恒河猴(1-5mg/kg)時(shí)間劑量依賴性地表現(xiàn)出抗凝效果。CX3CL1受到促炎性刺激的上調(diào),包括巨噬細(xì)胞,樹突狀細(xì)胞,內(nèi)皮細(xì)胞,神經(jīng)元,平滑肌,上皮細(xì)胞的細(xì)胞類型。Recombinant Human TNFRSF11A/Rank Protein,hFc Tag
猴痘病毒(Monkeypox Virus, MPXV)屬于正痘病毒屬。一般來(lái)說(shuō),同屬病毒具有相似的生物學(xué)特性。Recombinant Human APOE4/Apolipoprotein E Protein,HisTag
Recombinant Biotinylated Human ENPP-3 Protein,His-Avi Tag性能參數(shù)分子別名(Synonyms)NPP3;E-NPP3;PD-Ibeta表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)BiotinylatedHumanENPP-3ProteinisexpressedfromHEK293withHistagandAvitagattheN-Terminus.ItcontainsLeu48-Ile875.[Accession|O14638]分子量大小(MolecularWeight)TheproteinhasapredictedMWof99.97kDa.Duetoglycosylation,theproteinmigratesto110-130kDabasedonSDS-PAGEresult.(Endotoxin)Lessthan1EUperμgbytheLALmethod.純度(Purity)>95%asdeterminedbySDS-PAGEandHPLC.制劑(Formulation)Lyophilizedfrom0.22μmfilteredsolutioninPBS(pH7.4).Normally8%trehaloseisaddedasprotectantbeforelyophilization.重構(gòu)方法(Reconstitution)Centrifugethetubebeforeopening.Reconstitutingtoaconcentrationmorethan100μg/mlisrecommended.Dissolvethelyophilizedproteinindistilledwater.儲(chǔ)存條件Theproductshouldbestoredat-25~-15℃for1yearfromdateofreceipt.2-7days,2~8°Cundersterileconditionsafterreconstitution.3-6months,-85~-65℃understerileconditionsafterreconstitution.Recombinant Human APOE4/Apolipoprotein E Protein,HisTag
浦斯瑞(上海)生物醫(yī)藥有限公司是一家有著先進(jìn)的發(fā)展理念,先進(jìn)的管理經(jīng)驗(yàn),在發(fā)展過(guò)程中不斷完善自己,要求自己,不斷創(chuàng)新,時(shí)刻準(zhǔn)備著迎接更多挑戰(zhàn)的活力公司,在江蘇省等地區(qū)的化工中匯聚了大量的人脈以及**,在業(yè)界也收獲了很多良好的評(píng)價(jià),這些都源自于自身的努力和大家共同進(jìn)步的結(jié)果,這些評(píng)價(jià)對(duì)我們而言是比較好的前進(jìn)動(dòng)力,也促使我們?cè)谝院蟮牡缆飞媳3謯^發(fā)圖強(qiáng)、一往無(wú)前的進(jìn)取創(chuàng)新精神,努力把公司發(fā)展戰(zhàn)略推向一個(gè)新高度,在全體員工共同努力之下,全力拼搏將共同浦斯瑞(上海)生物醫(yī)藥供應(yīng)和您一起攜手走向更好的未來(lái),創(chuàng)造更有價(jià)值的產(chǎn)品,我們將以更好的狀態(tài),更認(rèn)真的態(tài)度,更飽滿的精力去創(chuàng)造,去拼搏,去努力,讓我們一起更好更快的成長(zhǎng)!